COCP vs. HUGE, NRBO, VBIV, AYTU, NERV, VAXX, TNXP, ORGS, TLPH, and PIRS
Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include FSD Pharma (HUGE), NeuroBo Pharmaceuticals (NRBO), VBI Vaccines (VBIV), Aytu BioPharma (AYTU), Minerva Neurosciences (NERV), Vaxxinity (VAXX), Tonix Pharmaceuticals (TNXP), Orgenesis (ORGS), Talphera (TLPH), and Pieris Pharmaceuticals (PIRS). These companies are all part of the "pharmaceutical preparations" industry.
FSD Pharma (NASDAQ:HUGE) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
FSD Pharma's return on equity of -59.62% beat Cocrystal Pharma's return on equity.
In the previous week, FSD Pharma and FSD Pharma both had 4 articles in the media. FSD Pharma's average media sentiment score of 0.94 beat Cocrystal Pharma's score of 0.06 indicating that Cocrystal Pharma is being referred to more favorably in the news media.
1.2% of FSD Pharma shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 8.5% of FSD Pharma shares are held by insiders. Comparatively, 25.1% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cocrystal Pharma has a consensus target price of $10.00, indicating a potential upside of 513.50%. Given FSD Pharma's higher possible upside, analysts plainly believe Cocrystal Pharma is more favorable than FSD Pharma.
Cocrystal Pharma received 21 more outperform votes than FSD Pharma when rated by MarketBeat users.
FSD Pharma has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Cocrystal Pharma is trading at a lower price-to-earnings ratio than FSD Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Cocrystal Pharma beats FSD Pharma on 9 of the 12 factors compared between the two stocks.
Get Cocrystal Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cocrystal Pharma Competitors List
Related Companies and Tools
